Ezetimibe and Plaque Regression∗
نویسندگان
چکیده
منابع مشابه
Ezetimibe and Plaque Regression: Cholesterol Lowering or Pleiotropic Effects?
SEE PAGE 495 S econdary prevention of cardiovascular events in patients with documented coronary artery disease is an unmet need. Current guidelines recommend tight control of cardiovascular risk factors (1). In this context, lowering of low-density lipoprotein cholesterol (LDL-C) remains crucial, because it has been associated with better prognosis and stabilization, or even regression of coro...
متن کاملEvaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression.
Tsujita et al. (1) reported the results of the PRECISEIVUS (Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound) trial which found that, compared with standard statin monotherapy, the combination of statin plus ezetimibe showed greater coronary plaque regression in a secondary prevention setting, and suggested that the clinical ev...
متن کاملEzetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden.
BACKGROUND AND PURPOSE There has been recent controversy over failure of ezetimibe to reduce carotid intima-media thickness. Much of this is based on failure to understand important differences among ultrasound phenotypes of atherosclerosis. METHODS We analyzed the effect of adding ezetimibe to the regimen of patients being followed in vascular prevention clinics where measurement of carotid ...
متن کاملLipid Lowering and Plaque Regression
T reatments designed to favorably affect the clinical impact of coronary artery disease (CAD) have two fundamental goals. The first goal is to diminish the symptomatic limitations imposed by arterial obstructive disease, in which the vessel's capacity to fully meet the varying oxygen demands of the myocardium is impaired. Vascular capacity may be abnormal because of a fixed flow-limiting corona...
متن کاملAtherosclerosis regression, vascular remodeling, and plaque stabilization.
hat atherosclerosis regression may be a realistic goal in ome patients. Although the actual amount of plaque egression and compositional change is small, there may be ubstantial clinical benefit. Yet, the question arises: what is he therapeutic mechanism? Is it the reduced dimension of he plaque, the decreased atheroma burden, or the conseuent compositional changes that confer the clinical imro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2015
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2015.05.064